Loading…
Loading…
Innovent Biologics, Inc. and Eli Lilly and Co. (NYSE:LLY) on Tuesday entered into a distribution and promotion agreement for Eli Lilly's breast cancer therapy Verzenios (abemaciclib) in mainland China.
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin has completed an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds, and other institutional investors new to Ollin, including a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., and a leading sovereign wealth fund, alongside continued investment from co-founding investors Mubadala Capital and Monograph Capital.
SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is China's first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational Phase III clinical trial, aiming to bring a promising next-generation immunotherapy option for Chinese R/R MM patients.
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines, the companies said on Friday.
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, first announced the preliminary PoC clinical study results for its global first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and the full abstract is available here.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for IVBXF and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.